A 38-year-old woman with a 2-year history of a slowly-growing mass on the anterolateral aspect of the left ankle. During that time the patient has reported minimal pain while walking or standing for prolonged periods, and the joint sometimes becomes inflamed when she overexerts.
MRI was performed, demonstrating an oval and well-defined nodular lesion in the antero-lateral region of the ankle, in close relationship with the tendon sheath of the extensor digitorum longus. The image presents hypointense signal in T1 (Figures 1a, 1b and 1c) and intermediate signal in T2 sequences (Figure 2), with subtle areas of signal drop in sequences of magnetic susceptibility (Figure 3) and enhancement after administration of IV contrast (Figure 4).
The ultrasound evaluation showed a solid lesion, homogeneously hypoechoic (Figures 5a and 5b) with slight peripheral flow in the power Doppler study (Figure 6).
A US-guided biopsy was performed (Figure 7), and histopathological results were obtained (Figure 8).
Background
Tenosynovial giant cell tumour (TSGCT) is the unifying term used in the 2020 WHO Soft Tissue and Bone Tumours Classification [1]. They have previously been known as pigmented villonodular tumours of the tendon sheath (PVNTS). It is a benign proliferative disease affecting synovial membranes, arising from the synovium of joint, bursae and/or tendon sheath. There are 2 forms, localised (L-TSGCT) and diffuse (D-TSGCT), which, although histologically similar, behave differently [3]. Localised tenosynovial GCT is more common, with a predominance for the hand and wrist, whereas the diffuse type is less common and affects the large joints (e.g., knee, hip, ankle) more [2]. It may be intra or extra-articular, and is classified as localised or diffuse, with diffuse forms being more aggressive. Extra-articular tenosynovial GCTs are most commonly periarticular in the lower limb (particularly the knee) but can be intramuscular or subcutaneous in location [1].
Clinical Perspective
TSGCT is a rare pathology affecting young subjects [4], mostly in the 4th and 5th decades of life [1]. The most frequent presentation is the localised form with a predilection for women. Localised forms predominate in the digits (85%), near the synovial sheaths or interphalangeal joints, more often on the palmar than the dorsal side and usually present as a single nodular lesion. Other less frequent locations comprise the wrist, foot and ankle, knee and, very rarely, hip or elbow [1,5]. Clinical presentation is relatively nonspecific [4].
Imaging Perspective
The gold standard for the diagnosis is MRI. Localised forms typically show a well-delineated lesion, in contact with the tendon sheath. Diffuse forms are usually articular.
The tendency of the lesions to bleed results in deposition of hemosiderin, more commonly in diffuse forms of the disease. The paramagnetic effect of hemosiderin results in the reduction of signal intensity in all pulse sequences, which is enhanced by highfield-strength and gradient-echo sequences. The reduction of signal intensity is more accentuated on T2-weighted images [6]. The signal is enhanced on gadolinium injection. Bone erosion and neurovascular encasement can be seen.
In ultrasound evaluation, most tumours are hypoechoic, homogeneous, posterior acoustic enhancement may be seen in some lesions, and typically show vascularity on power Doppler [7].
Outcome
The treatment of choice is surgery, and as TSGCT is most often present in the benign form, extensive surgery is generally not indicated. Localised forms usually permit total macroscopic resection and show little recurrence [8].
Teaching Points
TSGCT of the ankle is an uncommon localisation of the disease. Although the most frequent location is in the fingers, one should suspect it in other locations when the lesion is in close contact with synovial membranes. This is especially true when MRI shows a lesion with signal drop in magnetic susceptibility sequences.
All patient data have been completely anonymised throughout the entire manuscript and related files.
Tenosynovial giant cell tumour localised type (L-TSGCT)
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Based on the MRI and ultrasound images provided by the patient, there is a localized soft tissue mass in the anterolateral soft tissue of the left ankle joint. MRI shows that the mass is closely related to the tendon sheath, appearing as a relatively well-defined round/irregular lesion with uniform or slightly high signal on T1-weighted images and relatively low signal on T2-weighted images (suggesting potential hemosiderin deposition), with varying degrees of enhancement after contrast administration. No obvious joint surface destruction or significant bone erosion is seen; however, there is a mild compression effect on the adjacent soft tissue. On ultrasound, the lesion appears as a hypoechoic or relatively homogeneous echo, with a clear boundary and mild blood flow signal indicating abundant blood supply. Overall, the imaging findings are consistent with a benign lesion originating from the tendon sheath.
Considering the patient’s age, slow-growing clinical history, imaging features (especially the low T2 signal and enhancement on MRI), and the local lesion site, the most likely diagnosis is Localized Tenosynovial Giant Cell Tumor (TSGCT, focal type). If pathological results (if obtained) indicate the presence of macrophages, foam cells, and hemosiderin deposition, it can further confirm this diagnosis. If no pathological examination has been performed, surgical pathology confirmation is recommended.
Treatment Strategy:
Most cases are benign, and surgical resection is generally the first choice, with a low recurrence rate postoperatively. For localized TSGCT, complete excision under arthroscopy or open surgery is typically sufficient. If the lesion is relatively large or located near critical structures, thorough preoperative evaluation and planning are necessary.
Rehabilitation and Exercise Prescription:
This report serves only as a reference for medical analysis and cannot replace a professional physician’s consultation or formal treatment advice. Specific diagnoses and treatments must be based on the patient’s actual condition and the recommendations of a certified hospital and specialist.
Tenosynovial giant cell tumour localised type (L-TSGCT)
